Long-term raloxifene for postmenopausal osteoporosis

Current Medical Research and Opinion

Volumn 27, Issue 9, 2011, Pages 1755-1761

  Recker, Robert R ^a   Mitlak, Bruce H ^b   Ni, Xiao ^b   Krege, John H ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Breast neoplasms; Clinical trials; Osteoporosis; Raloxifene; SERMs

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; PLACEBO; RALOXIFENE;

BONE CELL; BONE DENSITY; BONE MARROW BIOPSY; BONE TURNOVER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; DEEP VEIN THROMBOSIS; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; LEG CRAMP; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MORPHOMETRICS; OSTEOLYSIS; PERIPHERAL EDEMA; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME; VASODILATATION; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 80051713305     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.606312     Document Type: Review

References (26)

1. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-758 (Pubitemid 27458965)
2. Katzenellenbogen BS, Katzenellenbogen JA. Biomedicine. Defining the 'S' in SERMs. Science 2002;295:2380-2381
3. Evista USPI. Available at: http://pi.lilly.com/us/evista-pi.pdf [Last accessed 22 February 2011]
4. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999;282:637-45. (Pubitemid 29384151)
5. Erratum in: JAMA 1999; 282:2124
6. Barrett-Connor E, Cauley JA, Kulkarni PM, et al. Risk-benefit profile for raloxifene: 4-year data from the Muliple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 2004;19:1270-1275 (Pubitemid 41094367)
7. Delmas PD, Ensrud KE, Adachi JD, et al. Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617 (Pubitemid 34879503)
8. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on the risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97. (Pubitemid 29275701)
9. Erratum in JAMA 1999;282:2124
10. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34. (Pubitemid 32193616)
11. Erratum in Breast Cancer Res Treat 2001;67:191
12. Guidelines for the preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Rockville, MD: FDA Division of Metabolic and Endocrine Drug Products, 1994. Available at: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealth Research/UCM131206.pdf [Last accessed 22 February 2011]
13. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761 (Pubitemid 39654569)
14. Siris ES, Harris ST, Eastell R, et al. Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-1524 (Pubitemid 41243540)
15. Recker RR, Kimmel DB, Parfitt AM, et al. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 1988;3:133-144
16. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10 (Pubitemid 33150990)
17. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11:1531-1538 (Pubitemid 26331009)
18. Eastell R, Rogers A, Ni X, et al. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporos Int 2010; 22:1927-1934
19. Michalská D, Stepan JJ, Basson BR, et al. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006;91:870-877 (Pubitemid 43357752)
20. Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:985-992 (Pubitemid 36121052)
21. Ott SM, Oleksik A, Lu Y, et al. Bone histomophometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 2002;17:341-348 (Pubitemid 34087667)
22. Weinstein RS, Parfitt AM, Marcus R, et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003;14:814-822 (Pubitemid 37462131)
23. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-202 (Pubitemid 32269244)
24. Boivin G, Lips P, Ott SM, et al. Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 2003;88: 4199-205 (Pubitemid 37153720)
25. Byrjalsen I, Leeming DJ, Qvist P, et al. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 2008;19:339-348 (Pubitemid 351199183)
26. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-344 (Pubitemid 36870506)